Cognitive Impairment in Patients with Metabolic Syndrome
Metabolic syndrome is one of the most common metabolic disorders observed in 15-30% adults, which is characterized by combined abdominal obesity together with dyslipidemia, arterial hypertension, and hyperglycemia. Insulin resistance plays an important role in developing major components of metabolic syndrome. A close relationship between metabolic syndrome and cardiovascular and neurological pathologies (including cognitive impairment) determines importance of its timely diagnostics and therapy. All main clinical components comprising metabolic syndrome primarily arterial hypertension, obesity and hyperglycemia, especially their combination, may exhibit unfavorable influence on brain activity. Mainly, treatment of metabolic syndrome includes measures on reducing body weight including increased physical activity, administration of drugs elevating sensitivity of body tissues to insulin as well as hypolipidemic and anti-hypertensive agents. Opportunity of using current peptidergic agents in correction of cognitive impairment in patients with metabolic syndrome is discussed.